The purpose of this study is to evaluate the safety and efficacy of nemtabrutinib (formerly ARQ 531) in participants with hematologic malignancies of chronic l…

Hematologic MalignanciesWaldenstroms MacroglobulinaemiaNon-Hodgkins Lymphoma+1 more

~Estimated

~$75 – $2,800

Actual pay is set by the research site.

Merck Sharp & Dohme LLCNCT04728893

Long Term Follow up Study for Participants Treated With an Allogeneic CAR T-Cell Product in a Prior Clinical Study

An observational, long-term follow up (LTFU) study of participants who received an allogeneic CAR T product in a prior clinical study. Participants will be fol…

Hematologic MalignanciesSolid Tumors

~Estimated

~$10 – $1,050

Actual pay is set by the research site.

Allogene TherapeuticsNCT06925685

Observational

Improving Patient Outcomes Through a Digital Health Delivered Intervention to Monitor and Manage Symptoms After Chimeric Antigen Receptor T-Cell Therapy

The goal of this study is to refine and test a digital intervention named WAYPOINT to help patients monitor and manage symptoms after CAR-T therapy. The main q…

Chimeric Antigen Receptor T-cell TherapyHematologic Malignancy

~Estimated

~$10 – $750

Actual pay is set by the research site.

Massachusetts General HospitalNCT07886190

← PreviousPage 12 of 12Next →